Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. David Spigel: We've Probably Made Maintenance Therapy More Complicated Than It Needs To Be
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)
Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer
Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. William Pao on "How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?"
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (video)
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
GRACEcast Pancreatic Cancer Audio
GRACEcast Radiation Oncology Audio
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Kidney Cancer Video
GRACEcast Social Work and Coping Video